To our knowledge, out of the mentioned markers, targeted therapies have been developed for PD-1 and PD-L1, while the clinical trials targeting the other mentioned markers have so far been unsuccessful, at least in the context of HCC (20–27). Here, CD274 is linked to hepatocellular carcinoma.